Significant survival benefit of node-negative breast cancer patients treated with adjuvant chemotherapy: seven-year results.
Jakesz
R
R
Abteilung für Chirurgie, Gynäkologie, Chemotherapie und Pathologie, Universität Wien, Austria.
Reiner
G
G
Schemper
M
M
Reiner
A
A
Blijham
G
G
Rainer
H
H
Dittrich
D
D
Spona
J
J
Schutte
B
B
Reynders
M
M
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001388:Aziridines / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D005500:Follow-Up Studies; D006801:Humans; D008198:Lymph Nodes / Q000473:pathology*; D008408:Mastectomy; D008593:Menopause; D008727:Methotrexate / Q000008:administration & dosage; D016032:Randomized Controlled Trials as Topic; D011960:Receptors, Estrogen / Q000032:analysis; D011980:Receptors, Progesterone / Q000032:analysis; D012307:Risk Factors; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage
D001388:Aziridines; D011960:Receptors, Estrogen; D011980:Receptors, Progesterone; C016866:azimexon; D014750:Vincristine; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate